Publique en esta revista
Información de la revista
Vol. 10. Núm. 5.
Páginas 345-346 (Septiembre - Octubre 2014)
Vol. 10. Núm. 5.
Páginas 345-346 (Septiembre - Octubre 2014)
Carta al editor
Acceso a texto completo
Triple therapy with non-biologic DMARDs for rheumatoid arthritis or biologic therapy. Is it the same?
Triple terapia con FARME no biológico o tratamiento biológico para artritis reumatoide. ¿Son lo mismo?
Visitas
...
Carlos Abud-Mendoza
Autor para correspondencia
c_abud@hotmail.com

Autor para correspondencia.
, Marco U. Martínez-Martínez
Unidad Regional de Reumatología y Osteoporosis, Hospital Central “Dr. Ignacio Morones Prieto” y Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, S.L.P., México
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo

The goals for rheumatoid arthritis (RA)—remission or low disease activity— are achieved through combination therapy with disease-modifying antirheumatic drugs (DMARDs) or biologic therapy. DMARDs combination therapy achieve the goals in higher percentage than DMARD monotherapy1,2. Recently O’Dell et al. compared triple therapy with three non-biologic DMARDs, and biologic therapy with etanercept-methotrexate in RA3. This comparison is important for developing countries because the poor availability through social security4.

O’Dell and colleagues did not find significant differences in DAS28 (using erythrocyte sedimentation ratio, ESR or C reactive protein, CRP). Even DAS28 is considered the “gold standard” for evaluating disease activity, other clinical measures such as ultrasound or MRI might improve sensitivity for the targets in RA patients5–8. The study reported that patients receiving biologic therapy achieved American College of Rheumatology ACR50 and ACR70 almost 10% higher than triple therapy. Previous studies informed improved productivity of daily work8 and slow or not radiographic progression in patients under biologics therapy, although the significance related with the structural differences is not clinically defined1,9,10. It is clear that there are benefits for patients receiving biologic therapy.

The clinical benefits of triple therapy previously mentioned are relevant in most RA patients when compared to efficacy of DMARD combination. This is especially an attractive treatment because of the lower cost of triple therapy compared to biologics, particularly in developing countries. Although we do not have official data related with social security in México, approximately 20% of RA patients covered by ISSSTE (11% of total Mexican population), and less than 5% of IMSS (59% of total Mexican population) are receiving a biological therapy; Mexican population with no social security is a rare event to prescribe biologic therapy. However, although triple therapy can be more accessible than biologics, the latter treatment becomes necessary for at least in 20-30% of RA patients particularly when individual treatment is refractory to methotrexate. Nonetheless, treatments with higher doses of methotrexate11,12, in combination with prednisone13 or with another combination of DMARD, reduces the percentage of patients requiring biologics therapy1,14,15. We suggest that initial triple DMARDs therapy for RA as the first therapy for monotherapy non-responsive patients and biologics must be reserved for refractory triple DMARDs therapy.

Bibliografía
[1]
V. Rantalaiho, H. Kautiainen, M. Korpela, P. Hannonen, O. Kaipiainen-Seppänen, T. Möttönen, for the NEO-RACo Study Group, et al.
Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
Ann Rheum Dis., (2013),
[2]
M. Boers, L. van Tuy, M. van den Broek, P.J. Kostense, C.F. Allaart.
Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also disconnect’ disease activity and damage in rheumatoid arthritis.
Ann Rheum Dis., 72 (2013), pp. 406-409
[3]
J.K. Anderson, L. Zimmerman, L. Caplan, K. Michaud.
Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA).
Arthritis Care Res (Hoboken), 63 (2011), pp. S14-S36
[4]
J.R. O’Dell, T.R. Mikuls, T.H. Taylor, V. Ahluwalia, M. Brophy, S.R. Warren, et al.
Therapies for active rheumatoid arthritis after methotrexate failure.
N Engl J Med, 369 (2013), pp. 307-318
[5]
R. Burgos-Vargas, L.J. Catoggio, C. Galarza-Maldonado, K. Ostojich, M.H. Cardiel.
Current therapies in rheumatoid arthritis: a Latin American perspective.
Reumatol Clin., 9 (2013), pp. 106-124
[6]
M.U. Martínez-Martínez, E. Cuevas-Orta, G. Reyes-Vaca, L. Baranda, R. González-Amaro, C. Abud-Mendoza.
Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor alpha agents.
Ann Rheum Dis, 66 (2007), pp. 134-135
[7]
E. Hernández-Núñez, E. Cuevas-Orta, E. Santillán-Guerrero, R. Moreno-Valdés, A. Sánchez-Arriaga, J.A. Ávila-Sánchez, et al.
Remisión sostenida en pacientes con artritis reumatoide agresiva. Estudio comparativo de abatacept y pacientes con 3 ó más fármacos modificadores de la enfermedad.
Reumatol Clin, (2011), pp. C1-CM022
[8]
G. Sakellariou, C.A. Scirè, S.M. Verstappen, C. Montecucco, R. Caporali.
In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis.
Ann Rheum Dis., 72 (2013), pp. 245-249
[9]
H. Furuya, T. Kasama, T. Isozaki, M. Umemura, K. Otsuka, S. Isojima, et al.
Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis.
J Multidiscip Healthc, 6 (2013), pp. 25-30
[10]
J.L. Nam, S. Ramiro, C. Gaujoux-Viala, K. Takase, M. Leon-Garcia, P. Emery, et al.
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.
Ann Rheum Dis., (2014),
[11]
S. Dhillon.
Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis.
BioDrugs., (2013),
[12]
C.M. Lambert, S. Sandhu, A. Lochhead, N.P. Hurst, E. McRorie, V. Dhillon.
Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Arthritis Rheum, 50 (2004), pp. 364-371
[13]
K. Visser, D. van der Heijde.
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literatura.
Ann Rheum Dis, 68 (2009), pp. 1094-1099
[14]
M.F. Bakker, J.W.G. Jacobs, P.M.J. Welsing, S.M.M. Verstappen, J. Tekstra, E. Ton, on behalf of the Utrecht Rheumatoid Arthritis Cohort Study Group, et al.
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. A randomized trial.
Ann Intern Med., 156 (2012), pp. 329-339
[15]
P.H. de Jong, J.M. Hazes, P.J. Barendregt, M. Huisman, D. van Zeben, P.A. van der Lubbe, et al.
Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.
Ann Rheum Dis, 72 (2012), pp. 72-78
Copyright © 2013. Elsevier España, S.L.. Todos los derechos reservados
Idiomas
Reumatología Clínica

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?